Cargando…
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
Adjuvant chemotherapy reduces risk of relapse and cancer-related mortality in early stage breast cancer. Over the last decade, taxanes (paclitaxel and docetaxel) have been incorporated into various adjuvant trials and have demonstrated a significant benefit in the management of early stage breast ca...
Autores principales: | Pant, Shubham, Chilukuri, Meena P, Ramaswamy, Bhuvaneswari |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504077/ https://www.ncbi.nlm.nih.gov/pubmed/18728853 |
Ejemplares similares
-
Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013) -
Weekly docetaxel in the treatment of metastatic breast cancer
por: Palmeri, Laura, et al.
Publicado: (2008) -
Targeting and limiting surgery for patients with node-positive breast cancer
por: Caudle, Abigail S., et al.
Publicado: (2015) -
The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
por: Bhateja, Priyanka, et al.
Publicado: (2019) -
Axillary surgery in node-positive breast cancer()
por: Maggi, Nadia, et al.
Publicado: (2021)